Correction to: Episodic Ataxia Type 1: Natural History and Effect on Quality of Life

por Graves, Tracey D., Griggs, Robert C., Bundy, Brian N., Jen, Joanna C., Baloh, Robert W., Hanna, Michael G.
Publicado 2022

Episodic Ataxia Type 1: Natural History and Effect on Quality of Life

por Graves, Tracey D., Griggs, Robert C., Bundy, Brian N., Jen, Joanna C., Baloh, Robert W., Hanna, Michael G.
Publicado 2022

Long‐term efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis

por Sansone, Valeria A., Johnson, Nicholas E., Hanna, Michael G., Ciafaloni, Emma, Statland, Jeffrey M., Shieh, Perry B., Cohen, Fredric, Griggs, Robert C.
Publicado 2021

In vivo impact of presynaptic calcium channel dysfunction on motor axons in episodic ataxia type 2

por Tomlinson, Susan E., Tan, S. Veronica, Burke, David, Labrum, Robyn W., Haworth, Andrea, Gibbons, Vaneesha S., Sweeney, Mary G., Griggs, Robert C., Kullmann, Dimitri M., Bostock, Hugh, Hanna, Michael G.
Publicado 2016

Review of the Diagnosis and Treatment of Periodic Paralysis

por Statland, Jeffrey M., Fontaine, Bertrand, Hanna, Michael G., Johnson, Nicholas E., Kissel, John T., Sansone, Valeria A., Shieh, Perry B., Tawil, Rabi N., Trivedi, Jaya, Cannon, Stephen C., Griggs, Robert C.
Publicado 2017

Population-Wide Duchenne Muscular Dystrophy Carrier Detection by CK and Molecular Testing

por Han, Shuai, Xu, Hong, Zheng, Jinxian, Sun, Junhui, Feng, Xue, Wang, Yue, Ye, Wen, Ke, Qing, Ren, Yanwei, Yao, Shulie, Zhang, Songying, Chen, Jianfen, Griggs, Robert C., Zhao, Zhengyan, Qi, Ming, Gatheridge, Michele A.
Publicado 2020

Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy

por Griggs, Robert C., Miller, J. Phillip, Greenberg, Cheryl R., Fehlings, Darcy L., Pestronk, Alan, Mendell, Jerry R., Moxley, Richard T., King, Wendy, Kissel, John T., Cwik, Valerie, Vanasse, Michel, Florence, Julaine M., Pandya, Shree, Dubow, Jordan S., Meyer, James M.
Publicado 2016

Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol

por Stunnenberg, Bas C, Woertman, Willem, Raaphorst, Joost, Statland, Jeffrey M, Griggs, Robert C, Timmermans, Janneke, Saris, Christiaan G, Schouwenberg, Bas J, Groenewoud, Hans M, Stegeman, Dick F, van Engelen, Baziel G M, Drost, Gea, van der Wilt, Gert Jan
Publicado 2015

A checklist for clinical trials in rare disease: obstacles and anticipatory actions—lessons learned from the FOR-DMD trial

por Crow, Rebecca A., Hart, Kimberly A., McDermott, Michael P., Tawil, Rabi, Martens, William B., Herr, Barbara E., McColl, Elaine, Wilkinson, Jennifer, Kirschner, Janbernd, King, Wendy M., Eagle, Michele, Brown, Mary W., Hirtz, Deborah, Lochmuller, Hanns, Straub, Volker, Ciafaloni, Emma, Shieh, Perry B., Spinty, Stefan, Childs, Anne-Marie, Manzur, Adnan Y., Morandi, Lucia, Butterfield, Russell J., Horrocks, Iain, Roper, Helen, Flanigan, Kevin M., Kuntz, Nancy L., Mah, Jean K., Morrison, Leslie, Darras, Basil T., von der Hagen, Maja, Schara, Ulrike, Wilichowski, Ekkehard, Mongini, Tiziana, McDonald, Craig M., Vita, Giuseppe, Barohn, Richard J., Finkel, Richard S., Wicklund, Matthew, McMillan, Hugh J., Hughes, Imelda, Pegoraro, Elena, Bryan Burnette, W., Howard, James F., Thangarajh, Mathula, Campbell, Craig, Griggs, Robert C., Bushby, Kate, Guglieri, Michela
Publicado 2018